The present invention relates to a process used in production of the effervescent formulations comprising the alpha-glucosidase inhibitor miglitol and metformin as the active agent that shall be used in improving glycemic control in adults suffering from non-insulin dependent diabetes (type 2) wherein hyperglycaemia cannot be controlled by diet or exercise.

The present invention relates to pharmaceutical compositions comprising voglibose acarbose or miglitol that shall be used in the treatment of non-insulin dependent type II diabetes.

The present invention relates to a pharmaceutical composition comprising voglibose acarbose or miglitol so as to be used in the prophylaxis and treatment of type 2 diabetes (non-insulin dependent) mellitus cases wherein hyperglycemia cannot be controlled by diet or exercise.

The present invention relates to a process used form production of effervescent formulations comprising an alpha.glucosidase inhibitor derivative active agent (voglibose acarbose miglitol possibly combined with metformin) whereby the effervescent couple is granulated and the active agent is added to the dried granules.

The present invention relates to a process used for production of effervescent formulations comprising alpha-glucosidase inhibitor derivative active agent (e.g. voglibose acarbose miglitol possibly in combination with metformin) whereby the amount of the granulation solvent should be no more than 2.5% in proportion to the effervescent acid and effervescent base).

Composición farmacéutica de liberación controlada que exhibe un reducido efecto de alimentos.Reivindicación 1: Una composición farmacéutica de liberación controlada con reducido efecto de alimentos en donde dicha composición comprende un agente activo y al menos un excipiente farmacéuticamente aceptable en donde dicho agente activo tiene una ventana de absorción limitada y muestra un efecto de alimentos negativo cuando se administra una forma de dosificación de liberación inmediata de dicho agen...